I. Agirrezabal

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

2020 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové

Publikace